At the same time, levels in non-survivors remained stable, resulting in significantly increased levels of EIF4A1 in the non-surviving COVID-19 patients compared to the survivors on days 4–5 (FC = 1.41; p = 0.019; Figure 5E). This evidence concerns the gene EIF4A1 and COVID-19.